Across TCGA pan-cancer cohorts, NFE2L2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of NFE2L2’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NFE2L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NFE2L2 is over-expressed in tumor.
HNSC are the cancer types where NFE2L2 tumor–normal differential expression is most reproducible.